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Purpose
We evaluated the efficacy and safety of avelumab, an anti–PD-L1 antibody, in patients 
with metastatic or unresectable colorectal cancer (mCRC) with mismatch repair deficiency 
(dMMR)/microsatellite instability-high (MSI-H) or POLE mutations. 
Materials and Methods
In this prospective, open-label, multicenter phase II study, 33 patients with mCRC harboring 
dMMR/MSI-H or POLE mutations after failure of ≥ 1st-line chemotherapy received ave-
lumab 10 mg/kg every 2 weeks. dMMR/MSI-H was confirmed with immunohistochemical 
staining (IHC) by loss of expression of MMR proteins or polymerase chain reaction (PCR) for 
micro-satellite sequences. POLE mutation was confirmed by next-generation sequencing 
(NGS). The primary endpoint was the objective response rate (ORR) by Response Evalua-
tion Criteria in Solid Tumors ver. 1.1.     
Results
The median age was 60 years, and 78.8% were male. Thirty patients were dMMR/MSI-
H and three had POLE mutations. The ORR was 24.2%, and all of the responders were 
dMMR/MSI-H. For 21 patients with MSI-H by PCR or NGS, the ORR was 28.6%. At a median 
follow-up duration of 16.3 months, median progression-free survival and overall survival 
were 3.9 and 13.2 months in all patients, and 8.1 months and not reached, respective-
ly, in patients with MSI-H by PCR or NGS. Dose interruption and discontinuation due to 
treatment-related adverse events occurred in four and two patients, respectively, with no 
treatment-related deaths.
Conclusion
Avelumab displayed antitumor activity with manageable toxicity in patients with previously 
treated mCRC harboring dMMR/MSI-H. Diagnosis of dMMR/MSI-H with PCR or NGS could 
be complementary to IHC to select patients who would benefit from immunotherapy.
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Introduction
Colorectal cancer (CRC) is one of the leading causes of 
cancer-related death worldwide and the third most common 
cancer in Korea [1]. Standard palliative treatment for meta-
static or unresectable CRC (mCRC) is fluorouracil-based com-
bination chemotherapy (with oxaliplatin or irinotecan), with 
or without agents targeting angiogenesis (bevacizumab) or 
epidermal growth factor receptor (cetuximab). The available 
therapeutic options for later-line chemotherapy are limited; 
regorafenib and TAS-102 showed only a modest clinical ben-
efit in these patients. The objective response rate (ORR) with 
regorafenib and TAS-102 was approximately 1%, and median 
progression-free survival (PFS) was around 2 months for both 
treatments [2,3]. The long-term outcomes of mCRC are still 
poor [1], and novel therapeutic approaches are needed.
Growing evidence suggests that patients with mCRC har-
boring deficient mismatch repair protein (dMMR)/micro-
satellite instability–high (MSI-H) can obtain clinical benefit 
from immune checkpoint inhibitors (ICIs) [4-7]. Pembroli-
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zumab and nivolumab, which are anti–programmed death 
1 (anti–PD-1) inhibitors, improved ORR and PFS in selected 
patients with dMMR/MSI-H mCRC [4-7]. Failure to repair 
DNA replication-associated errors in dMMR/MSI-H mCRC 
is associated with high mutation loads, tumor neoantigen 
loads, and dense immune cell infiltration [8]. In fact, the 
whole-exome sequences revealed higher somatic mutation 
loads (1,782 mutations per tumor) in patients with dMMR/ 
MSI-H than in patients with proficient MMR (73 mutations 
per tumor) (p=0.007), and a greater density of CD8-positive 
lymphocytes and a higher expression of PD-ligand 1 (PD-L1) 
were observed in patients with dMMR/MSI-H than in pati-
ents with proficient MMR [4]. However, the clinical benefit 
of ICIs is confined to a small proportion of patients, because 
dMMR/MSI-H is identified in only about 5% in patients 
with mCRC [9]. This raises the need to expand the number of 
potential candidates for immunotherapy.
The POLE gene is located in 12q24.33 and encodes the 
proofreading (exonuclease) subunit of polymerase epsilon 
(POLE) with 2,286 amino acids [10]. This POLE mutation has 
been reported in approximately 3% of proficient MMR CRC 
and represents high somatic mutation loads [10]. According to 
the Cancer Genome Atlas, up to one-quarter of hypermutat-
ed CRC carry somatic mutations in POLE [10]. Because high 
mutation loads are considered a mechanism of the response 
of dMMR/MSI-H to ICIs, POLE-mutated cancer may also be 
susceptible to ICIs. However, to date, clinical data regarding 
the response to ICIs in POLE-mutated cancer are lacking. 
Treatment with avelumab, an anti–PD-L1 inhibitor, achie-
ved an ORR of 33% in patients with previously treated 
metastatic Merkel cell carcinoma and was approved for the 
treatment of metastatic Merkel cell carcinoma in early 2017 
[11]. Subsequently, avelumab has shown promising antitu-
mor activity in various solid tumors, such as genitourinary 
tract [12,13], gynecologic [14], and lung [15], but its activity in 
mCRC harboring dMMR/MSI-H has not been investigated. 
This study aimed to evaluate the efficacy and safety of ave-
lumab in patients with previously treated CRC with deficient 
MMR/MSI-H as well as those with POLE mutations.  
Materials and Methods
1. Study design and patients
This study is a prospective, open-label, multicenter phase 
II study conducted as a substudy of the K-MASTER project, 
a nationwide, government-funded precision medicine initia-
tive [16]. Eligible patients were aged ≥ 20 years and had his-
tologically or cytologically confirmed metastatic or unresec- 
table adenocarcinoma of the colon or rectum after failure 
of first-line or later chemotherapy, including fluoropyrimi-
dine, oxaliplatin, or irinotecan, with or without targeted 
agents (bevacizumab or cetuximab). Patients were enrolled if 
dMMR/ MSI-H was confirmed by either immunohistochem-
istry (IHC) or polymerase chain reaction (PCR) by local test 
at each site, or if POLE mutation was confirmed by next-gen-
eration sequencing (NGS) certified by the Ministry of Food 
and Drug Safety, Korea. MMR protein was determined to be 
deficient by loss of expression of one or more of the following 
on IHC: MLH1, MSH2, MSH6, and PMS2. MSI-H was diag-
nosed by PCR if two or more microsatellite markers (BAT-
25, BAT-26, D2S123, D5S346, and D17S250) were detected. 
POLE mutations included hotspots such as P286R and other 
sites. Eligible patients had at least one measurable disease, an 
Eastern Cooperative Oncology Group (ECOG) performance 
status of 0 or 1, and adequate organ function. Any prior treat-
ment with anti–PD-1 or PD-L1 inhibitors was not permitted, 
and prior immunosuppressive treatment or the last dose of 
chemotherapy should not be administered within 28 days 
before the first dose of study drug. Prior radiotherapy was 
permitted if it was not administered to the target lesions 
selected for this study. 
2. Treatment and evaluation 
Avelumab was administered at 10 mg/kg intravenously 
every 2 weeks until disease progression, unacceptable tox-
icity, or patient refusal occurred. Dose modification was not 
allowed, but dose delay was permitted at the investigator’s 
discretion in case of clinically significant events. Study treat-
ment was discontinued if there were more than 4 weeks of 
delay. Response assessment was performed by computed 
tomography (CT) scan according to Response Evaluation Cri-
teria in Solid Tumors (RECIST) ver. 1.1 every 6 weeks. After 
the end of treatment, patients were followed up for disease 
status and survival information every 3 months. The medi-
cal histories of all patients were obtained before treatment, 
including physical examination, complete blood count with 
differential count, serum chemistry, electrolytes, coagulation, 
carcinoembryonic antigen, thyroid function test (thyroid-
stimulating hormone and free thyroxine), urinalysis, electro-
cardiogram, chest X-ray, CT scan, and other scans if clinically 
indicated. Adverse events were assessed every cycle accord-
ing to the National Cancer Institute Common Terminology 
Criteria for Adverse Events (NCI-CTCAE), version 4.0. 
3. Statistical analysis 
The sample size was calculated using the Simon two-stage 
optimal design. The target response rate was set to 30%, 
and a rate of 10% or below was considered failure, allow-
ing early termination of any ineffective treatment early in 
the study. With a one-sided type I error of 5% and a power 
of 0.8, the planned study was to proceed in two steps. If a 
tumor response occurred in at least two patients after the 
first 10 patients were listed, the study proceeded to the sec-
ond stage with 19 additional patients. A total of 29 patients 
were requi-red, and enrollment of 33 patients was planned, 
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given a dropout rate of 10%.
The primary endpoint was the ORR by RECIST ver. 1.1; 
the secondary endpoints included the disease control rate 
(DCR), PFS, overall survival (OS), and adverse events. DCR 
was defined as the proportion of patients with complete res-
ponse (CR), partial response (PR), or stable disease (SD) sus-
tained for ≥ 6 weeks. PFS was calculated from the first date of 
avelumab administration to the date of disease progression 
or death from any cause. OS was calculated from the first 
date of avelumab administration to the date of death from 
any cause. Survival rates were estimated using the Kaplan-
Meier method. A two-sided p-value < 0.05 was considered 
to indicate statistical significance, and all statistical analyses 
were performed using IBM SPSS Statistics for Windows ver. 
21.0 (IBM Corp., Armonk, NY).
4. Ethical statement
All procedures followed were in accordance with the ethi-
Table 1.  Baseline characteristics of the study patients 
Characteristic No. (%)
Age, median (range, yr) 60 (25-88)
Sex  
    Male 26 (78.8)
    Female 7 (21.2)
ECOG performance status 
    0 10 (30.3)
    1 23 (69.7)
Primary tumor 
    Right-sided colon 22 (66.7)
    Left-sided colon 5 (15.2)
    Rectum 6 (18.2)
Histology 
    Well differentiated 6 (18.2)
    Moderately differentiated 19 (57.6)
    Poorly differentiated 5 (15.2)
    Not assessable  3 (9.1)
RAS status 
    Wild 11 (33.3)
    Mutant 20 (60.6)
    Not done 2 (6.1)
BRAF status 
    Wild  22 (66.7)
    Mutant  4 (12.1)
    Not done 7 (21.2)
Sites of metastasis 
    Liver 15 (45.5)
    Lung 11 (33.3)
    Lymph node, abdomen 20 (60.6)
    Peritoneum/Omentum 9 (27.3)
    Bone 2 (6.1)
Family history of cancer in  7 (21.2)
  any first-degree relative
Previous chemotherapy regimen 
    FOLFOX 24 (72.7)
    FOLFIRI 15 (45.5)
    XELOX 4 (12.1)
    Capecitabine  10 (30.3)
    Others 2 (6.1)
Previous targeted treatment 
    Bevacizuamb  25 (75.8)
    Cetuximab  2 (6.1)
Prior radiotherapy 7 (21.2)
Prior surgery 
    Primary site resection  31 (93.9)
    Metastasectomy  9 (27.3)
(Continued)
Table 1.  Continued
Characteristic No. (%)
Prior lines of therapy
    1 16 (48.5)
    2 11 (33.3)
    ≥ 3 6 (18.2)
ECOG, Eastern Cooperative Oncology Group; FOLFOX, 5-fluo-
rouracil, leucovorin, and oxaliplatin; FOLFIRI, 5-fluorouracil, 
leucovorin, and irinotecan; XELOX, capecitabine and oxalipl-
atin. 
Fig. 1.  Status of mismatch repair by immunohistochemistry 
(IHC) or microsatellite instability (MSI) by polymerase chain 
reaction (PCR) and POLE mutation. dMMR, mismatch repair 
deficiency; MSI-H, MSI-high; MSS, microsatellite stable; NGS, 
next-generation sequencing; p-MMR, proficient-microsatellite 
instability. a)Six of nine were MSS by PCR or NGS, b)One of eight 
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cal standards of the responsible committee on human experi-
mentation (institutional and national) and the Helsinki Dec-
laration of 1964 and later versions. The study protocol was 
approved by the institutional review board of each partici-
pating center and the Korean Cancer Study Group (KCSG; 
protocol No. KCSG-CO-17-07). This trial was registered on 
http://www.clinicaltrials. gov with the identifier NCT0315-
0706. Informed consent or a substitute was obtained from all 
patients before inclusion in the study.
Results
1. Patient characteristics
Between May 2017 and April 2019, a total of 34 patients 
were initially enrolled at seven clinical sites in South Korea; 
one patient failed the screening tests, and thus, 33 patients 
with histologically or cytologically confirmed, previously 
treated, metastatic or unresectable CRC were enrolled in the 
final analysis. Table 1 summarizes the baseline characteristics 
of the 33 study patients. The median age was 60 years (range, 
25 to 88), and 78.8% were male. Two-thirds of the patients 
(n=22, 66.7%) had right-sided colon cancer, and 20 patients 
(60.6%) had RAS mutation. Seven patients had a family his-
Fig. 2.  Antitumor activity of avelumab in patients with metastatic or unresectable colorectal cancer harboring deficient mismatch repair 
(dMMR)/microsatellite instability-high (MSI-H) or POLE mutations. (A) Treatment duration of avelumab for all patients. (B) Best change 
from baseline in target lesion size after avelumab. CR, complete response; IHC, immunohistochemistry; NGS, next-generation sequenc-
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tory of cancer in a first-degree relative. 
2. Deficient MMR or MSI high and POLE mutation
Among the 33 patients, 30 patients had dMMR/MSI-H 
CRC, and three patients had POLE-mutated CRC. POLE 
mutation was identified at the P286C, R559W, and G1086S 
sites. NGS revealed hypermutated phenotype CRC in only 
one patient with a P286C mutation, but the other sites (R559W 
and G1086S) were not associated with high tumor mutation 
burden (TMB) in each different NGS panel (S1 Table).
Among 30 patients with dMMR/MSI-H, IHC, and PCR 
were performed both in 23 patients, respectively. Both tests at 
the same time were performed in 16 patients, among whom 
10 (62.5%) showed concordance between IHC and PCR. 
NGS, which was not mandatory for detecting dMMR/ MSI-
H, was performed in 12 patients with dMMR/MSI-H.
The distribution of patients according to different detec-
tion methods is shown in Fig. 1. Twenty-one patients were 
diagnosed with dMMR by IHC, and 19 were diagnosed 
with MSI-H by PCR. Discordance between the IHC and PCR 
results was found as follows: six of nine patients with dMMR 
by IHC only showed microsatellite stable (MSS) CRC by PCR 
or NGS, and one of eight patients with MSI-H by PCR only 
showed proficient MMR by IHC. One patient who was diag-
nosed as MSI-H by PCR and NGS was diagnosed as profi-
cient MMR by IHC. 
Table 2.  Clinical response to avelumab monotherapy
Response
                                                 All patients (n=33)                             MSI high by PCR or NGS (n=21)
 No. (%) 95% CI (%) No. (%) 95% CI (%)
Complete response 4 (12.1) 0.97-23.2 3 (14.3) 0-29.3 
Partial response 4 (12.1)  0.97-23.2 3 (14.3) 0-29.3
Stable disease 18 (54.5)  37.5-71.5 13 (61.9)    41.1-82.7
Progressive disease 6 (18.2)  5.0-31.4 2 (9.5)  0-22.0
Not assessablea) 1 (3.0)  0-8.8 0 ( -
Objective response rate 8 (24.2) 9.4-38.6 6 (28.6)   9.3-47.9
Disease control rate 26 (78.8)  64.9-92.7 19 (90.5)   77.9-103
MSI, microsatellite instability; PCR, polymerase chain reaction; NGS, next-generation sequencing. a)Lost to follow-up (n=1).
Fig. 3.  Representative images of two patients who achieved partial response during avelumab monotherapy. (A) Endoscopic images of a 
44-year-old man with initially metastatic T-colon cancer harboring microsatellite instability-high (MSI-H) by both immunohistochemistry 
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3. Clinical response to avelumab  
Avelumab was discontinued mainly due to disease pro-
gression (n=22, 66.7%), followed by loss to follow-up (n=1, 
0.03%); the remaining 10 patients were treated with ongo-
ing avelumab (Fig. 2A). The median time to response was 
4.2 months, and the median duration of response was 13.9 
months (Fig. 2A). Among the 33 patients, four (12.1%) had 
CR, four (12.1%) had PR, 18 (54.5%) had SD, 6 (18.2%) had 
progressive disease (PD), and one (3.0%) was not assess-
able (Table 2). The ORR and DCR were 24.2% and 78.8%, 
respectively. Of 21 patients with MSI-H by PCR or NGS, three 
(14.3%) had CR, three (14.3%) had PR, 13 (61.9%) had SD, 
and two (9.5%) had PD (Table 2). The ORR and DCR were 
28.6% and 90.5%, respectively. All responders had dMMR/
MSI-H CRC, and no patients with a POLE mutation achieved 
response. 
The best percentage changes from baseline in target lesion 
size are shown in Fig. 2B. Six of eight patients with CR or PR 
showed MSI-H by PCR or NGS. Among six patients with PD, 
two patients with POLE mutations (G1086S and P286C) had 
PD based on unequivocal progression of nontarget lesions, 
and all three patients with POLE mutations had PD without 
any tumor shrinkage. One patient with proficient MMR by 
IHC only but MSI-H by PCR achieved PR. Representative 
images of two responders are shown in Fig. 3.
Given the discrepancies between IHC and PCR results and 
the need to investigate their association with the response 
to avelumab, IHC results were separately reviewed in avail-
able eight of nine patients with dMMR by IHC only at each 
clinical site. dMMR was revised to proficient MMR by IHC in 
five patients, who also showed MSS by PCR or NGS. Four of 
them did not achieved response; however, the other patient 
achieved CR despite proficient MMR revised after review of 
the IHC result and MSS by PCR.
4. PFS and OS 
With a median follow-up duration of 16.3 months (95% 
confidence interval [CI], 5.6 to 27.1 months), median PFS was 
3.9 months (95% CI, 2.3 to 5.6 months) in all patients and 8.1 
months (95% CI, 1.1 to 15.1 months) in patients with MSI-H 
by PCR or NGS (Fig. 4A and B). Median OS was 13.2 months 
(95% CI, 7.9 to 18.4 months) in all patients and not reached in 
patients with MSI-H by PCR or NGS (Fig. 4C and D). Over-
all, the 12-month PFS and OS rates were 36.4% and 66.7%, 
Fig. 4.  Median progression-free survival (PFS) (A, B) and overall survival (OS) (C, D) in all patients (A, C) and patients with microsatellite 
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respectively, and 47.6% and 76.2%, respectively, in patients 
with MSI-H by PCR or NGS.
5. Treatment-related adverse events  
Treatment-related adverse events (TRAEs) with avelumab 
are shown in Table 3. TRAEs of any grade were observed in 
24 patients (72.7%). Common TRAEs of any grade included 
myalgia (n=6, 18.2%), chills (n=5, 15.2%), infusion-related 
reaction (n=5, 15.2%), pruritus (n=5, 15.2%), thyroid dys-
function (n=4, 12.1%), and skin rash (n=4, 12.1%). Grade 3 
or 4 TRAEs occurred in six patients (18.2%). Dose interrup-
tion due to TRAEs occurred in four patients (12.1%): grade 
3 hyperglycemia (n=1), grade 3 lipase increase (n=1), grade 
2 aspartate aminotransferase increase (n=1), and grade 2 
fever (n=1). There were two discontinuations of treatment 
due to treatment-related grade 3 hyperbilirubinemia (n=1) 
and probable treatment-related grade 4 tumor bleeding (n=1) 
after response to avelumab as a serious adverse event. There 
were no deaths due to TRAE.  
 
Discussion
In this open-label, multicenter, phase II study, avelumab 
showed promising antitumor activity and manageable tox-
icity in patients with mCRC harboring dMMR/MSI-H or 
POLE mutation. The ORR and median PFS were 24.2% and 
3.9 months, respectively, and six of eight responders were 
continuing avelumab treatment with durable response at the 
end of the analysis. Of note, the ORR and median PFS were 
28.6% and 8.1 months, respectively, in patients with MSI-
H by PCR or NGS, which were thought to be more reliable 
methods of determining the MSI status than IHC. Although 
no patients with POLE mutations had response to avelumab, 
the limitations of small sample size and variation in muta-
tion sites need to be taken into account. TRAEs of any grade 
and TRAEs of grade 3 or 4 were observed in 72.7% and 18.2% 
of patients, respectively, which was consistent with previous 
studies [17]. There were two discontinuations of treatment, 
one because of a TRAE and the other because of a serious 
adverse event, probably related to treatment. There were no 
treatment-related deaths. 
The efficacy of avelumab (an anti–PD-L1 inhibitor) for 
mCRC with dMMR/MSI-H, specifically in patients with 
MSI-H by PCR or NGS, is comparable to that of pembro- 
lizumab and nivolumab (anti–PD-1 inhibitors) in this setting. 
In the KEYNOTE-016 trial, only patients with MSI-H CRC 
had the objective response to pembrolizumab (ORR 40%), 
whereas none of those with MSS CRC had the objective res- 
ponse [4]. A subsequent multicenter trial of pembrolizu-
mab for dMMR/MSI-H CRC, the KEYNOTE-164 phase II 
study, resulted in an ORR of 33% and a median PFS of 4.1 
months; the 12-month PFS and OS rates were 34% to 41% 
and 72% to 76%, respectively, according to prior line of treat-
ment [6,7]. Nivolumab also showed promising antitumor 
activity in terms of ORR (31.1%) in dMMR/MSI-H CRC, 
and the 12-month PFS and OS rates were 50% and 73%, 
respectively [5]. All these favorable results in dMMR/MSI-H 
CRC contrast sharply with those of later-line conventional 
chemotherapy for overall mCRC with treatments such as 
regorafenib or TAS-102, which resulted in ORR of only 1% 
and median PFS of around 2 months [2,3]. 
Several phase I results from the JAVELIN Solid Tumor Tri-
als have shown promising ORRs and disease stabilization 
with avelumab in various types of advanced tumors. Specifi-
cally, among 53 patients with metastatic or locally advanced 
previously treated solid tumors, four (8%) achieved respon-
ses and 30 (57%) had SD [18]. The ORR with avelumab 
ranged from 6.7% to 18.2%, depending on tumor type such 
as metastatic or unresectable previously treated renal cell 
carcinoma [12], urothelial carcinoma [13], non-small cell lung 
cancer [15], and ovarian cancer [14]. In a phase II study of 
88 patients with chemotherapy-refractory metastatic Merkel 
cell carcinoma [11], the ORR with avelumab was 33%, includ-
ing a CR rate of 11.4%. To date, avelumab has been approved 
for treatment of previously treated metastatic Merkel cell 
carcinoma, urothelial carcinoma, and renal cell carcinoma in 
combination with axitinib. Several explorations to expand 
Table 3.  Treatment-related adverse events 
Event
                             All patients (n=33, 100%)
 Any grade Grade ≥ 3
Any TRAE 24 (72.7) 6 (18.2)
Myalgia  6 (18.2) 0 (
Chills  5 (15.2) 0 (
Infusion-related reaction  5 (15.2) 0 (
Pruritus   5 (15.2) 0 (
Thyroid dysfunction  4 (12.1) 0 (
Skin rash  4 (12.1) 0 (
Diarrhea 3 (9.1) 2 (6.1)
Fever 3 (9.1) 0 (
Increased AST or ALT  3 (9.1) 0 (
Hypomagnesemia 3 (9.1) 0 (
Fatigue 2 (6.1) 0 (
Anorexia  2 (6.1) 0 (
Hyperglycemia 2 (6.1) 1 (3.0)
Increased amylase or lipase  1 (3.0) 2 (6.1)
Nausea 1 (3.0) 0 (
Sweating 1 (3.0) 0 (
Dry skin  1 (3.0) 0 (
Anemia 1 (3.0) 0 (
Hyperbilirubinemia  0 (0.0) 1 (3.0)
Values are presented as number (%). TRAE, treatment-related 
adverse event; AST, aspartate aminotransferase; ALT, alanine 
aminotransferase. 
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its use in various clinical settings are ongoing. The present 
study adds to the evidence of clinical activity of avelumab by 
showing durable objective responses in mCRC with dMMR/
MSI-H.
dMMR/MSI-H is an established biomarker for the effi-
cacy of ICIs in mCRC, and its predictive value has also been 
confirmed in other various tumors. MSI-H metastatic gastric 
cancer (mGC) had a higher ORR with pembrolizumab than 
did MSS mGC (57% vs. 9%) in the KEYNOTE-059 study [19]. 
Recently, the clinical benefit of pembrolizumab was demon-
strated among patients with dMMR/MSI-H non-CRC, inclu-
ding endometrial cancer, gastric cancer, cholangiocarcinoma, 
and pancreatic cancer in terms of ORR (34.3%) and median 
PFS (4.1 months) [20]. Although the exact mechanism is 
unknown, there are several proposed explanations for T-cell 
checkpoint blockade [21]. Since dMMR/MSI-H results in 
diverse neoantigens, T-cell epitopes that are newly formed 
as a consequence of tumor-specific mutations, which can 
increase neoantigen-driven T-cell response. Another possi-
ble explanation is that dMMR/MSI-H is associated with the 
activation of signaling pathways through altered cytokines 
or chemokines, resulting in the tumor microenvironment 
becoming more inflamed. Cellular stress induced by dMMR/ 
MSI-H promotes innate immune cells, such as T cells and 
natural killer cells, or tumor recognition.
However, not all patients with mCRC harboring dMMR/ 
MSI-H respond to ICIs, and the TMB varies even within 
dMMR/MSI-H mCRC. The updated analysis from the ini-
tial single-center study showed an ORR of 50% [4], but sub-
sequent multicenter phase II trials revealed ORR of around 
30% [5-7]. In the present study, the ORR was 28.6% in pati-
ents with MSI-H by PCR or NGS. Approximately 37 to 41 
mutations per megabase may be a cutoff value, and low TMB 
was significantly associated with poor response to ICIs and 
worse PFS within the dMMR/MSI-H population, which may 
be an explanation for the heterogeneity in response in recent 
clinical trials of dMMR/MSI-H CRC [22]. Moreover, substan-
tial genomic variation is observed within dMMR/MSI-H 
tumors. In particular, the genome-wide intensity of MSI and 
the accumulation of insertion–deletion mutational loads are 
responsible for a wide diversity of clinical benefits with ICIs 
[23], and the activated WNT/β-catenin signaling pathway 
is associated with immune escape, despite a high TMB and 
high numbers of tumor-infiltrating lymphocytes [24].
In fact, a considerable portion of the primary resistance 
of mCRC treated with ICIs may be due to misdiagnosis of 
dMMR/MSI-H. One study showed that three of five patients 
(60%) who had PD at the first evaluation were reassessed as 
MSS by central review with PCR, contrary to the diagnosis 
of dMMR/MSI-H by local assessment [25]. In the Check-
Mate-142 study, there were discrepancies between local and 
central assessments in 14 of 74 patients (19%) [5]. Most of the 
patients with assessments (10/14) were initially determined 
as dMMR by IHC at the local laboratory, but central review 
with PCR reclassified them as MSS [5]. In this study, there 
were some discrepancies between IHC and PCR results, 
and six of nine patients with dMMR by IHC only showed 
MSS by PCR or NGS, leading to different ORRs depend-
ing on how dMMR/MSI-H CRC was defined. After review 
of the available IHC results in eight of these patients, five 
patients were revised to proficient MMR, while their PCR or 
NGS showed all MSS. The reliability and reproducibility of 
IHC results have always been a concern, because IHC results 
are largely affected by intra- and interobserver variation and 
tissue preservation status [26], and local assessment with-
out central review contributed to these results. Likewise, in 
the recent phase II study with a similar design, differences 
in ORRs with avelumab in patients with previously treated 
endometrial cancer were observed between dMMR deter-
mined by IHC only and MSI-H determined by NGS (26.7% 
vs. 30%) [27]. dMMR/MSI-H could be misdiagnosed if IHC 
results are not supported by PCR or NGS, so the IHC test 
alone should be carefully interpreted by experienced pathol-
ogists. Further, IHC tests on tumor samples achieved after 
chemoradiotherapy, old samples, or poorly preserved sam-
ples are associated with a high risk of unreliable results. 
POLE-mutated CRC has been characterized by young age, 
male predominance, right-sided CRC, earlier stage of dis-
ease, and excellent prognosis [10]. POLE has a crucial role in 
chromosomal DNA replication by its proofreading capacity 
and is known to be mutually exclusive with dMMR/MSI-
H [10]. Because of high immunogenicity and enrichment 
of mutation-associated neoantigens, POLE-mutated cancer 
has been considered a candidate for treatment with ICIs. 
However, there are limited data, and there is only one case 
report [28] of a patient with mCRC harboring a POLE muta-
tion (V411L) and MSS. This patient had a response after three 
cycles of pembrolizumab, and CD8 infiltrating lymphocytes 
with PD-1 expression were observed in the primary colon 
tumor. All responders in previous reports had mutations 
at the P286R or V411L sites, which are considered hotspots 
of POLE mutation [10]. Unfortunately, three patients with 
POLE mutations did not respond to ICIs in the present study. 
One patient with a P286C mutation was associated with a 
hypermutation phenotype by NGS, but the other two (with 
R559W and G1086S mutations) did not show high TMB, 
although they were tested with different panels (S1 Table), 
and the identified sites of POLE mutation might not have 
been hotspots, which could have led to negative results. Fur-
ther clinical studies with larger sample sizes are necessary to 
evaluate the activity of ICIs and its association with sites in 
POLE-mutated CRC.
One of the responders initially showed dMMR by IHC and 
MSS by PCR at the time of enrollment. However, the IHC 
result was revised to proficient MMR in the post hoc review. 
Although NGS could not be performed due to an inadequate 
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amount of tumor tissue, leaving the POLE mutation status 
of this patient unknown, he achieved CR and has continued 
avelumab treatment for approximately 18 months (Fig. 3). 
In this regard, there may be unknown factors to explain the 
mechanism of response to ICIs other than MMR/MSI status 
or POLE mutation, such as PD-L1 or PD-L2 amplification 
[29,30], although we could not explore the cause of respon-
siveness in this patient due to the lack of adequate tumor 
tissue. 
This study has several limitations. The consistency of eli-
gibility and response evaluation could not be fully ensured, 
because central adjudication of the dMMR/MSI status of 
tumor tissue and central review of the radiologic response 
were not performed. Tumor samples were not collected pro-
spectively for research purposes, and therefore translational 
studies, such as investigation of TMB, tumor-infiltrating 
lymphocytes, PD-L1 expression, or transcriptome, have not 
yet been performed. Further post hoc studies are planned 
with available tissue samples to elucidate their association 
with the response to ICIs. 
In conclusion, avelumab is a promising anti–PD-L1 inhi-
bitor in patients with metastatic or unresectable CRC harbor-
ing dMMR/MSI-H or POLE mutations. For the determina-
tion of dMMR/MSI-H, the conventional IHC method alone 
appears to be insufficient to select patients who would bene-
fit from immunotherapy. Further studies to identify accurate 
strategies to select optimal candidates for immu-notherapy 
are needed.
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